Relationship Between Drusen Height and OCT Biomarkers of Atrophy in Non-Neovascular AMD.


Journal

Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701

Informations de publication

Date de publication:
03 Oct 2022
Historique:
entrez: 28 10 2022
pubmed: 29 10 2022
medline: 2 11 2022
Statut: ppublish

Résumé

To determine if increasing drusen height correlates with predictive optical coherence tomography (OCT) biomarkers of atrophy. Retrospective cross-sectional study that enrolled patients with drusen associated with intermediate AMD. Macular drusen were classified as small, intermediate, large, or very large based on OCT quartile measurement of height. Drusen diameter was also tabulated. The presence and localization of the OCT biomarkers of atrophy were assessed: disruption of the external limiting membrane and ellipsoid zone, intraretinal hyper-reflective foci, RPE disruption, choroidal hypertransmission, and presence of hyporeflective cores. Predictive OCT biomarkers of atrophy were correlated with drusen height. A total of 155 eyes from 104 patients met the inclusion and exclusion criteria. The mean age was 75.7 ± 8.7 years, and patients were predominantly female (74.0%). The mean visual acuity was logMAR 0.2 ± 0.2 (Snellen equivalent 20/32). The average drusen height was 134.6 ± 107.5 µm and the greatest horizontal diameter was 970.7 ± 867.4 µm. Disruption of the external limiting membrane and ellipsoid zone, RPE thickening or thinning, intraretinal hyper-reflective foci, choroidal hypertransmission, and presence of hyporeflective cores (P < 0.05) were more common in eyes with large drusen and very large drusen versus small or intermediate drusen. All biomarkers were positively correlated with drusen height. OCT biomarkers of atrophy were predominantly located at the apex of the drusen. Predictive OCT biomarkers of atrophy, specifically signs of RPE breakdown and disruption, occur more commonly in large or very large drusen, especially in drusen with greater height and separation of the RPE from the underlying choroid.

Identifiants

pubmed: 36306145
pii: 2783807
doi: 10.1167/iovs.63.11.24
pmc: PMC9624265
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

24

Références

Ophthalmology. 2010 Mar;117(3):489-99
pubmed: 20079925
Ophthalmology. 2018 Apr;125(4):537-548
pubmed: 29103793
Br J Ophthalmol. 2021 Oct;105(10):1415-1420
pubmed: 32920528
Invest Ophthalmol Vis Sci. 2018 Jul 2;59(8):3199-3208
pubmed: 29971444
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Invest Ophthalmol Vis Sci. 2017 Jul 1;58(9):3519-3529
pubmed: 28715590
Ophthalmol Retina. 2021 Sep;5(9):855-867
pubmed: 33348085
Eye (Lond). 2020 Aug;34(8):1310-1312
pubmed: 32132677
Retina. 2013 Oct;33(9):1735-62
pubmed: 23873168
Ophthalmology. 2016 Sep;123(9):1856-64
pubmed: 27369111
Invest Ophthalmol Vis Sci. 2017 May 1;58(6):BIO211-BIO226
pubmed: 28785769
Ophthalmology. 2013 May;120(5):1038-45
pubmed: 23352193
Ophthalmol Retina. 2021 Oct;5(10):962-974
pubmed: 34126249
Invest Ophthalmol Vis Sci. 2016 Oct 01;57(13):5479-5489
pubmed: 27760262
J Ophthalmol. 2011;2011:692574
pubmed: 21869920
Ophthalmology. 1991 Jul;98(7):1128-34
pubmed: 1843453
Ophthalmology. 2017 May;124(5):644-656
pubmed: 28153442
Am J Ophthalmol. 2001 Nov;132(5):668-81
pubmed: 11704028
Ophthalmology. 2013 Dec;120(12):2656-2665
pubmed: 23830761
Ophthalmology. 2010 Feb;117(2):303-12.e1
pubmed: 19815280

Auteurs

Adrian Au (A)

Retinal Disorders and Ophthalmic Genetics Division, Stein Eye Institute, University of California Los Angeles, Los Angeles, California, United States.

Ahmad Santina (A)

Retinal Disorders and Ophthalmic Genetics Division, Stein Eye Institute, University of California Los Angeles, Los Angeles, California, United States.

Neda Abraham (N)

Retinal Disorders and Ophthalmic Genetics Division, Stein Eye Institute, University of California Los Angeles, Los Angeles, California, United States.

Miri Fogel Levin (MF)

Retinal Disorders and Ophthalmic Genetics Division, Stein Eye Institute, University of California Los Angeles, Los Angeles, California, United States.

Giulia Corradetti (G)

Doheny Eye Institute, Department of Ophthalmology, University of California, Los Angeles, Los Angeles, California, United States.

SriniVas Sadda (S)

Doheny Eye Institute, Department of Ophthalmology, University of California, Los Angeles, Los Angeles, California, United States.

David Sarraf (D)

Retinal Disorders and Ophthalmic Genetics Division, Stein Eye Institute, University of California Los Angeles, Los Angeles, California, United States.
Greater Los Angeles VA Healthcare Center, Los Angeles, California, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH